Rare diseases
Investigational molecules
Locations
Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase
GermanyJNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
GermanyLong-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
GermanyEIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors
GermanyPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
GermanyNeoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer
GermanyStudy of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
GermanyQTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia
GermanyObrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients
GermanyICP-332 for Adults with Prurigo Nodularis
GermanyRO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes
GermanyIfinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.
